Only 20 full-company mergers or acquisitions occurred throughout the year, although asset acquisition deals were more common.

Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

The agency made multiple decisions regarding coverage for diagnostic and laboratory testing that have affected the industry.

NEW YORK – Diagnostics firm Fujirebio and drugmaker Eisai said Monday that they have entered a memorandum of understanding for research into and use of blood-based biomarkers for neurodegenerative ...

NEW YORK – For clinical labs, 2024 will most likely be remembered as the year the US Food and Drug Administration finally made good on its decades-old promise — or threat, depending on your point of ...

The firm also has plans for tests beyond sepsis, including for cardiac events and other conditions that are commonly treated in acute care settings.

NEW YORK – Siemens Healthineers will in coming years phase out support for four legacy testing platforms as the company migrates customers to its newer Atellica instrument lineup that offers expanded ...